INKT Stock Forecast: MiNK Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.02
−6.85% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 62 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$41.2M
Ticker Nerd rank
62/ 100
Median analyst target
$44
Analysts covering
—
Revenue$0.0
Operating income−$3.2M
Net income−$3.1M
Free cash flow−$2.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.1%
1M
−18.7%
YTD
−28.1%
1Y
−26.3%
From 52W high
−43.6%
From 52W low
0.0%
$8
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores MiNK Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
62/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Issuance
74
Volatility
60
Revisions
54
Value
45
Growth
40
Momentum
37
Quality
29

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (29): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INKT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INKT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26INKTHigh $50Median $44Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Nov 2026HC Wainwright & Co.AssumesBuy$38
21 Oct 2026B. Riley SecuritiesReiteratesBuy$43 → $50
18 May 2026HC Wainwright & Co.ReiteratesBuy$35
1 Apr 2026HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025HC Wainwright & Co.UpgradeBuy—
15 July 2025HC Wainwright & Co.DowngradeNeutral—
14 July 2025William BlairDowngradeMarket Perform—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Feb 2025HC Wainwright & Co.MaintainsBuy—
15 Nov 2024BairdMaintainsOutperform—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
9 Oct 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
21 Mar 2024HC Wainwright & Co.MaintainsBuy—
10 Aug 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.MaintainsBuy—
19 Apr 2023HC Wainwright & Co.ReiteratesBuy—
22 Mar 2023Evercore ISI GroupMaintainsOutperform—
22 Mar 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

INKT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

INKT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, MiNK Therapeutics, Inc. returned −26.3% against +6.9% for the S&P 500, dividends included.

INKT vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Jan 26Apr 26Jul 26Oct 26INKTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INKT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
205.9×

Cheaper than 2% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−61.6%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MiNK Therapeutics, Inc. has a market value of $41.2M and an enterprise value of $33.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$11.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$6.8M.

  • Shares outstanding: 5.1M.

  • MiNK Therapeutics, Inc. employs 15 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

INKT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INKTMiNK Therapeutics, Inc.$41.2M62
DWTXDogwood Therapeutics, Inc.$39.6M71
ELTXElicio Therapeutics, Inc.$41.0M51
BMEABiomea Fusion, Inc.$41.7M46
OSTXOS Therapies, Inc.$42.0M23
CRBPCorbus Pharmaceuticals Holdings, Inc.$42.4M12
CNTBConnect Biopharma Holdings Ltd.$37.1M45

Take a look at INKT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own MiNK Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about INKT

How does Ticker Nerd's model rank INKT?

As at 21 Nov 2026, MiNK Therapeutics, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

What is the INKT stock forecast for 2030?

No analyst covering MiNK Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $50 over the next 12 months.

How has INKT stock performed over the past year?

MiNK Therapeutics, Inc. returned -26.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MiNK Therapeutics, Inc. do?

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company’s platform is designed to support scalable manufacturing of engineered and native iNKT cell programs, with a pipeline that includes therapies for solid tumors and inflammatory conditions.

Company

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company’s platform is designed to support scalable manufacturing of engineered and native iNKT cell programs, with a pipeline that includes therapies for solid tumors and inflammatory conditions. MiNK Therapeutics works at the intersection of cell therapy and immunology, using iNKT cells that are intended to combine tumor-targeting activity with immune-regulating properties. Its current work centers on advancing product candidates through clinical development and building a manufacturing approach suited to reproducible, off-the-shelf delivery. Headquartered in New York, MiNK Therapeutics plays a specialized role in the biotechnology market by developing precision immunotherapies for serious diseases with limited treatment options.

CEO Dr. Jennifer S. Buell Ph.D. · 15 employees · United States · https://minktherapeutics.com